Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Breast Neoplasms
Female
Follow-Up Studies
Gene Amplification
Humans
In Situ Hybridization, Fluorescence
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Paclitaxel
Prognosis
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies
Survival Rate
Tissue Array Analysis
Vascular Endothelial Growth Factor A

authors with profiles

Melody Cobleigh